Exicure (XCUR) Net Cash Flow (2016 - 2026)
Exicure (XCUR) reported Net Cash Flow of -$1.1 million for Q1 2026, up 45.31% on a YoY basis from -$785924.9 in Q1 2025, and down 65.03% quarter-over-quarter from -$692000.0 in Q4 2025.
Exicure (XCUR) Net Cash Flow (2016 - 2026) Analysis & Trends
Exicure has reported Net Cash Flow for 11 years, with the latest figure at -$1.1 million in Q1 2026.
- For the quarter ending Q1 2026, Net Cash Flow rose 45.31% year-over-year to -$1.1 million; the trailing twelve-month figure through Mar 2026 stood at -$7.8 million (down 188.28% YoY), and the FY2025 full-year result was -$8.8 million, down 183.51% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$1.1 million, down from -$692000.0 in the prior quarter.
- The five-year high for Net Cash Flow was $11.6 million in Q4 2024, with the low at -$18.8 million in Q1 2022.
- Historically, Net Cash Flow has averaged -$2.4 million across 5 years, with a median of -$1.4 million in 2023.
- Annual changes were most pronounced in 2022 — Net Cash Flow tumbled 1913.73% — and 2024, when it soared 11002.83%.
- Exicure's Net Cash Flow stood at -$7.1 million in 2022, then soared by 98.5% to -$106000.0 in 2023, then soared by 11002.83% to $11.6 million in 2024, then plunged by 105.99% to -$692000.0 in 2025, then sank by 65.03% to -$1.1 million in 2026.
- The last three Net Cash Flow figures came in at -$1.1 million (Q1 2026), -$692000.0 (Q4 2025), and -$3.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 625.70 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -2.44 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 457.40 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 664,983.53 |
| 10 | Exicure | 19.38 Mn | 16.77 Mn | - | -1.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.14 Mn |
| Mar 31, 2026 | -1.14 Mn |
| Dec 31, 2025 | -692,000.00 |
| Dec 31, 2025 | -692,000.00 |
| Sep 30, 2025 | -3.42 Mn |
| Sep 30, 2025 | -3.42 Mn |
| Jun 30, 2025 | -2.56 Mn |
| Jun 30, 2025 | -2.56 Mn |
| Mar 31, 2025 | -2.09 Mn |
| Mar 31, 2025 | -2.09 Mn |
| Dec 31, 2024 | 11.56 Mn |
| Dec 31, 2024 | 11.56 Mn |
| Sep 30, 2024 | -449,000.00 |
| Sep 30, 2024 | -449,000.00 |
| Jun 30, 2024 | -166,000.00 |
| Jun 30, 2024 | -166,000.00 |
| Mar 31, 2024 | -450,000.00 |
| Mar 31, 2024 | -450,000.00 |
| Dec 31, 2023 | -106,000.00 |
| Dec 31, 2023 | -106,000.00 |